Finance

Beta
Lists
326030:KRX
SK Biopharmaceuticals Co Ltd
â‚©82,400.00
-6.47%
(-5,700.00) 1D
Jun 8, 3:30:13 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 326030...
Open
â‚©83,500
High
â‚©84,500
Low
â‚©81,000
Mkt. cap
6.45T
Avg. vol.
386.15K
Volume
200.02K
P/E ratio
18.50
52-wk high
â‚©144,100
52-wk low
â‚©81,000
EPS
â‚©4,454
Shares outstanding
78.31M
No. of employees
246
Open
â‚©83,500
High
â‚©84,500
Low
â‚©81,000
Mkt. cap
6.45T
Avg. vol.
386.15K
Volume
200.02K
P/E ratio
18.50
52-wk high
â‚©144,100
52-wk low
â‚©81,000
EPS
â‚©4,454
Shares outstanding
78.31M
No. of employees
246
News stories
From sources across the web
About SK Biopharmaceuticals Co Ltd
CEO-
Employees246
Founded1993
Headquarters-
SectorPharmaceutical industry
Websiteskbp.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
176.28B
191.73B
194.36B
227.89B
Cost of goods sold
9.90B
7.55B
14.95B
14.33B
Cost of revenue
9.90B
7.55B
14.95B
14.33B
Research and development expenses
39.56B
40.93B
51.85B
47.59B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
60.40B
68.98B
77.42B
71.09B
Operating expense
104.49B
114.07B
133.13B
123.79B
Total operating expenses
114.39B
121.62B
148.08B
138.12B
Operating income
61.88B
70.11B
46.28B
89.77B
Other non operating income
6.70B
-8.46B
-7.51B
-5.78B
EBT including unusual items
34.68B
62.11B
33.76B
99.98B
EBT excluding unusual items
34.82B
61.27B
36.66B
89.89B
Income tax expense
5.15B
-9.26B
-98.98B
-2.76B
Effective tax rate
14.86%
-14.90%
-293.19%
-2.76%
Other operating expenses
1.34B
1.37B
1.11B
2.22B
Net income
32.92B
74.14B
136.59B
105.16B
Net profit margin
18.67%
38.67%
70.28%
46.15%
Earnings per share
-
-
-
-
Interest and investment income
1.79B
1.88B
1.72B
1.68B
Interest expense
-2.13B
-1.70B
-1.32B
-1.30B
Net interest expenses
-337.99M
179.24M
397.10M
380.91M
Depreciation and amortization charges
1.97B
2.23B
2.18B
2.19B
EBITDA
66.24B
74.11B
50.23B
93.70B
Gain or loss from assets sale
8.25M
10.55M
176.00M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer